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Vaccinia virus has a large and still incompletely understood genome although several strains of this virus are 
already in clinical development for the treatment of cancer. For the most part, clinical candidates have been 
attenuated from their wild type vaccine strains through deletion of metabolic genes like the viral thymidine 
kinase gene. We decided to carry out a more in depth understanding of the genetic elements of vaccinia which 
could be modulated to improve the oncolytic/therapeutic characteristics of the virus.  Using a variety of cancer 
cell lines and primary tumor explants, we performed a fitness assay that compares head to head five wild-type 
Vaccinia strains to identify the genetic elements that together create an optimal  “oncolytic engine”.  Using a 
transposon insertion strategy and deep sequencing of viral populations we systematically examined vaccinia 
genes that do or do not play a role in the therapeutic activity of the virus.  Our studies allowed us to identify large 
areas of the vaccinia genome that when deleted, augment the oncolytic activity of a newly created recombinant 
virus (35 genes deleted). This novel virus was compared to five vaccinia strains currently in the clinic and in a 
variety of assays, the deleted virus displayed superior therapeutic activity and an enhanced safety profile.  
Studies in a variety of in vitro and in vivo models will be presented illustrating the strategy we have used to 
create this optimized oncolytic virus platform. We are currently carrying out further pre-clinical studies to 
accelerate the translation of this new virus into the clinic.   
 
 
 
